Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

rMETase

  • Open Access
    Simultaneous Targeting of Multiple Hallmarks of Cancer With Recombinant Methioninase, Rapamycin and Chloroquine Is Specific and Synergistic to MiaPaCa-2 Pancreatic-Cancer Cells in Contrast to Hs-27 Normal Fibroblasts
    JINSOO KIM, QINGHONG HAN, SHUKUAN LI, BYUNG MO KANG, KOHEI MIZUTA, YOHEI ASANO, YUTA MIYASHI, MICHAEL BOUVET and ROBERT M. HOFFMAN
    Anticancer Research November 2025, 45 (11) 4765-4770; DOI: https://doi.org/10.21873/anticanres.17825
  • Open Access
    Combinations of Salmonella typhimurium A1-R, Recombinant Methioninase, and Chloroquine, Each Targeting Fundamental Cancer Hallmarks, Are Selectively Effective on Colon Cancer Cells Compared to Normal Fibroblasts
    JINSOO KIM, QINGHONG HAN, SHUKUAN LI, BYUNG MO KANG, KOHEI MIZUTA, YOHEI ASANO, YUTA MIYASHI, MING ZHAO, MICHAEL BOUVET and ROBERT M. HOFFMAN
    Anticancer Research September 2025, 45 (9) 3661-3668; DOI: https://doi.org/10.21873/anticanres.17729
  • Open Access
    Super Methotrexate-resistant Osteosarcoma Cells Retain Their Sensitivity to Recombinant Methioninase: Targeting Methionine Addiction to Overcome Extreme Cancer-Chemotherapy Resistance
    YUSUKE AOKI, QINGHONG HAN, YUTARO KUBOTA, NORIYUKI MASAKI, YASUNORI TOME, MICHAEL BOUVET, KOTARO NISHIDA and ROBERT M. HOFFMAN
    Anticancer Research March 2025, 45 (3) 929-934; DOI: https://doi.org/10.21873/anticanres.17480
  • Open Access
    Selective Synergy of Rapamycin Combined With Methioninase on Cancer Cells Compared to Normal Cells
    DANIEL ARDJMAND, YUTARO KUBOTA, MOTOKAZU SATO, QINGHONG HAN, KOHEI MIZUTA, SEI MORINAGA and ROBERT M. HOFFMAN
    Anticancer Research March 2024, 44 (3) 929-933; DOI: https://doi.org/10.21873/anticanres.16887
  • You have access
    Effective Metabolic Targeting of Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models with Recombinant Methioninase
    KENTARO IGARASHI, KEI KAWAGUCHI, TASUKU KIYUNA, KENTARO MIYAKE, TAKASHI MURAKAMI, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, HIROYUKI TSUCHIYA and ROBERT M. HOFFMAN
    Anticancer Research September 2017, 37 (9) 4807-4812;
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire